Domača stranBNTX • NASDAQ
add
BioNTech
106,72 $
Po zaprtju:(0,00 %)0,00
106,72 $
Konec trgovanja: 27. jun., 16:02:05 GMT -4 · USD · NASDAQ · Izjava
Prejšnji trg. dan.
106,14 $
Dnevni razpon
105,63 $ - 107,66 $
Letni razpon
76,53 $ - 131,49 $
Tržna kapitalizacija
25,61 mrd. USD
Povprečni obseg
1,09 mio.
V novicah
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (EUR) | mar. 2025info | Sprememba L/L |
|---|---|---|
Prihodek | 182,80 mio. | −2,56 % |
Stroški poslovanja | 593,40 mio. | −6,05 % |
Čisti dohodek | −415,80 mio. | −31,96 % |
Čista dobičkovnost prihodkov | −227,46 | −35,43 % |
Earnings per share | −1,73 | −32,06 % |
EBITDA | −451,60 mio. | 2,84 % |
Efektivna davčna stopnja | 6,65 % | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (EUR) | mar. 2025info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 14,11 mrd. | −9,94 % |
Skupna sredstva | 21,18 mrd. | −4,83 % |
Skupne obveznosti | 2,26 mrd. | −1,43 % |
Celoten lastniški kapital | 18,93 mrd. | — |
Shares outstanding | 240,39 mio. | — |
Razmerje P/B | 1,35 | — |
Donosnost sredstev | −5,65 % | — |
Donosnost kapitala | −6,36 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (EUR) | mar. 2025info | Sprememba L/L |
|---|---|---|
Čisti dohodek | −415,80 mio. | −31,96 % |
Denar iz dejavnosti | −780,70 mio. | −146,04 % |
Denar iz naložb | 1,25 mrd. | 154,11 % |
Denar iz financiranja | −13,80 mio. | −76,92 % |
Neto sprememba denarnih sredstev | 423,00 mio. | 115,74 % |
Prost denarni tok | −1,37 mrd. | −175,36 % |
Vizitka
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
Generalni direktor
Datum ustanovitve
2008
Spletno mesto
Zaposleni
6.772
